Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

NetScientific’s Wanda to partner with Dignity Health

Healthcare tech investor NetScientific is to partner with a leading US hospital group to launch a software platform to improve cancer care.
NetScientific’s Wanda to partner with Dignity Health
OncoVerse is a cancer care software platform
Healthcare tech investor NetScientific (LON:NSCI) is to partner with a leading US hospital group to launch a software platform to improve cancer care.
 
Its operating subsidiary Wanda has inked a collaborative deal with Dignity Health to launch OncoVerse.
 
The digital platform allows clinicians to work together to establish the most effective treatment plan and helps to reduce admin costs.
 
Dignity Health is home to nearly 9,000 physicians and more than 400 care centers spanning 21 states.
 
NetScientific's chief executive Francois R. Martelet said: "Wanda is the group's lead subsidiary in our digital health franchise.
 
"The launch of Oncoverse with Dignity Health, and its huge US network, is a significant milestone for the company and further endorses its core technology.
 
"This deal marks the second partnership that Wanda has secured with a leading US healthcare group since the start of 2016 as it continues to develop more platforms to better manage chronic conditions."
 
In January Wanda inked a deal with Chicago-based Health Resource Solutions (HRS) to provide its chronic condition digital management system.
 
The organisation looks after more than 1,000 patients per month helping them to have a higher quality of life at home rather than in hospitals.
 
The first patients are expected to start using the platform in the first quarter of this year.
 
And this month the firm revealed one of its portfolio companies was to partner with the US National Cancer Institute for phase II clinical trials of a novel range of cancer immunotherapies.
 
PDS Biotechnology has signed a co-operative research and development agreement with the NCI to develop treatments using its Versamune platform for tumour-related proteins in prostate, breast, and HPV-related cancers.
 
NetScientific shares added  2.4% to stand at 85.5p.
Giles_55af4ddca6481.jpg
Why Invest In Netscientific PLC? Read More Here

Register here to be notified of future NSCI Company articles
View full NSCI profile

Netscientific PLC Timeline

Related Articles

shutterstock_255595165.jpg
July 26 2016
Chief executive Cameron Reynolds told Proactive: "It's one thing to be a science project. It's another to have products and we are right on the cusp of that.”
1-SG02055.jpg
March 22 2016
e-Therapeutics is now targeting partners to accelerate the development of its drug discovery engine and commercialise compounds.
Cancer
May 02 2016
As UK biotechs are beating a trail to the US craving greater understanding and higher valuation, Doerfler and his team have opted to go in the opposite direction.

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.